Lymphocyte Recovery in Multiple Myeloma Patients Receiving Interferon After Intensive Therapy
Author Information
Author(s): BC Millar, JBG Bell, RL Powles
Primary Institution: Institute of Cancer Research and the Royal Marsden NHS Trust
Hypothesis
Does maintenance therapy with interferon a2 enhance the recovery of lymphocyte subsets in multiple myeloma patients after intensive therapy?
Conclusion
The study found no enhanced recovery of specific lymphocyte subsets in patients receiving interferon a2 as maintenance therapy after intensive treatment.
Supporting Evidence
- Patients receiving interferon a2 had significantly lower total white blood cell counts compared to those who had no further treatment.
- Natural killer (NK) activity was not significantly different between patients on interferon and normal volunteers.
- Despite the use of interferon, the recovery of CD4+ lymphocytes remained significantly below normal levels.
Takeaway
This study looked at how a medicine called interferon affects the immune cells in patients with a type of blood cancer called multiple myeloma after they received strong treatment. It found that interferon didn't help these immune cells recover better than those who didn't get interferon.
Methodology
The study analyzed blood samples from multiple myeloma patients and normal volunteers to compare lymphocyte recovery after treatment with high-dose melphalan and interferon.
Limitations
The study did not identify a specific lymphocyte subset that could serve as a prognostic indicator for the anti-proliferative effect of interferon.
Participant Demographics
Patients with multiple myeloma who received various treatment regimens including high-dose melphalan and interferon.
Statistical Information
P-Value
p<0.0002
Statistical Significance
p<0.02
Want to read the original?
Access the complete publication on the publisher's website